Ionis Pharmaceuticals (NASDAQ: IONS) continues to rack up royalties from its spinal muscular atrophy drug Spinraza while the rest of its extensive pipeline basically pays the rest of the biotech's bills.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,